Ann: Biotron Secures $4.7 Million Underwriting Agreement, page-9

Beyond HIV-1, BIT225 is an important asset as it demonstrates the robustness of Biotron’s approach to antiviral drug development and that the Company can generate clinically safe drugs with activity against a new class of viral protein targets. The underwritten funding will enable the Company to advance the development of other promising compounds within the its proprietary compound library that have been shown to have activity against other serious viral diseases including Hepatitis C, Hepatitis B, Dengue and others. In turn, this will enable the Company to attract a commercial partner for these applications within the Company’s antiviral platform.

Good luck